503 related articles for article (PubMed ID: 29274754)
21. Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores.
Proietti M; Senoo K; Lane DA; Lip GY
Sci Rep; 2016 Apr; 6():24376. PubMed ID: 27067661
[TBL] [Abstract][Full Text] [Related]
22. Comparison of HAS-BLED and HAS-BED Versus CHADS
Poli D; Antonucci E; Pengo V; Testa S; Palareti G
Am J Cardiol; 2017 Apr; 119(7):1012-1016. PubMed ID: 28237286
[TBL] [Abstract][Full Text] [Related]
23. Comparative validation of HAS-BLED, GARFIELD-AF and ORBIT bleeding risk scores in Asian people with atrial fibrillation treated with oral anticoagulant: A report from the COOL-AF registry.
Chichareon P; Winijkul A; Lip GYH; Krittayaphong R
Br J Clin Pharmacol; 2023 Aug; 89(8):2472-2482. PubMed ID: 36942465
[TBL] [Abstract][Full Text] [Related]
24. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
Steinberg BA; Shrader P; Kim S; Thomas L; Fonarow GC; Ansell J; Kowey PR; Singer DE; Gersh BJ; Mahaffey KW; Peterson ED; Piccini JP;
Am Heart J; 2016 Nov; 181():145-152. PubMed ID: 27823686
[TBL] [Abstract][Full Text] [Related]
25. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?
Quinn GR; Singer DE; Chang Y; Go AS; Borowsky LH; Fang MC
Am J Cardiol; 2016 Sep; 118(5):697-9. PubMed ID: 27394408
[TBL] [Abstract][Full Text] [Related]
26. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.
Lip GYH; Banerjee A; Boriani G; Chiang CE; Fargo R; Freedman B; Lane DA; Ruff CT; Turakhia M; Werring D; Patel S; Moores L
Chest; 2018 Nov; 154(5):1121-1201. PubMed ID: 30144419
[TBL] [Abstract][Full Text] [Related]
27. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.
Cullen MW; Kim S; Piccini JP; Ansell JE; Fonarow GC; Hylek EM; Singer DE; Mahaffey KW; Kowey PR; Thomas L; Go AS; Lopes RD; Chang P; Peterson ED; Gersh BJ;
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):461-9. PubMed ID: 23759473
[TBL] [Abstract][Full Text] [Related]
28. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation.
Fox KAA; Virdone S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Oto A; Misselwitz F; Piccini JP; Dalgaard F; Turpie AGG; Verheugt FWA; Kakkar AK;
Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):214-227. PubMed ID: 33892489
[TBL] [Abstract][Full Text] [Related]
29. Enhancing the 'real world' prediction of cardiovascular events and major bleeding with the CHA
Roldán V; Rivera-Caravaca JM; Shantsila A; García-Fernández A; Esteve-Pastor MA; Vilchez JA; Romera M; Valdés M; Vicente V; Marín F; Lip GYH
Ann Med; 2018 Feb; 50(1):26-34. PubMed ID: 28892413
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
Apostolakis S; Lane DA; Buller H; Lip GY
Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
[TBL] [Abstract][Full Text] [Related]
31. Comparing Bleeding Risk Assessment Focused on Modifiable Risk Factors Only Versus Validated Bleeding Risk Scores in Atrial Fibrillation.
Guo Y; Zhu H; Chen Y; Lip GYH
Am J Med; 2018 Feb; 131(2):185-192. PubMed ID: 28943382
[TBL] [Abstract][Full Text] [Related]
32. Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients.
Lamberts M; Staerk L; Olesen JB; Fosbøl EL; Hansen ML; Harboe L; Lefevre C; Evans D; Gislason GH
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28196815
[TBL] [Abstract][Full Text] [Related]
33. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation.
Gallego P; Roldán V; Torregrosa JM; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
Circ Arrhythm Electrophysiol; 2012 Apr; 5(2):312-8. PubMed ID: 22319005
[TBL] [Abstract][Full Text] [Related]
34. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
Lip GY; Frison L; Halperin JL; Lane DA
J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
[TBL] [Abstract][Full Text] [Related]
35. CHA
Kim TH; Yang PS; Kim D; Yu HT; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
Stroke; 2017 Nov; 48(11):2984-2990. PubMed ID: 28939672
[TBL] [Abstract][Full Text] [Related]
36. Performance of the HAS-BLED, ORBIT, and ATRIA Bleeding Risk Scores on a Cohort of 399 344 Hospitalized Patients With Atrial Fibrillation and Cancer: Data From the French National Hospital Discharge Database.
Pastori D; Marang A; Bisson A; Herbert J; Lip GYH; Fauchier L
J Am Heart Assoc; 2022 Dec; 11(23):e026388. PubMed ID: 36444864
[TBL] [Abstract][Full Text] [Related]
37. Impact of renal function deterioration on adverse events during anticoagulation therapy using non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Miyamoto K; Aiba T; Arihiro S; Watanabe M; Kokubo Y; Ishibashi K; Hirose S; Wada M; Nakajima I; Okamura H; Noda T; Nagatsuka K; Noguchi T; Anzai T; Yasuda S; Ogawa H; Kamakura S; Shimizu W; Miyamoto Y; Toyoda K; Kusano K
Heart Vessels; 2016 Aug; 31(8):1327-36. PubMed ID: 26276272
[TBL] [Abstract][Full Text] [Related]
38. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation.
Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
Sci Rep; 2017 Sep; 7(1):12066. PubMed ID: 28935868
[TBL] [Abstract][Full Text] [Related]
39. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: Attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study.
Chao TF; Lip GYH; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Chen SA
Int J Cardiol; 2018 Mar; 254():157-161. PubMed ID: 29407081
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study.
Zanella L; Zoppellaro G; Marigo L; Denas G; Padayattil Jose S; Pengo V
Cardiovasc Ther; 2018 Oct; 36(5):e12458. PubMed ID: 30007110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
